Browse Drug Recalls
3,394 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 3,394 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 3,394 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 6, 2019 | Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed b... | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules ... | Class II | AuroMedics Pharma LLC |
| Nov 6, 2019 | GSMS: Ranitidine Capsules 150 mg, Rx only, 500 count bottles (NDC 51407-097-0... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Golden State Medical Supply Inc. |
| Nov 6, 2019 | DG Health Acid Reducer Ranitidine Tablets 150 mg, 8-count carton, Distributed... | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules ... | Class II | AuroMedics Pharma LLC |
| Nov 6, 2019 | GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-0... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Golden State Medical Supply Inc. |
| Nov 1, 2019 | Ranitidine Syrup (Ranitidine Oral Solution USP), 15 mg/mL, 150 mg/10 mL per c... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | American Health Packaging |
| Oct 28, 2019 | Lannett Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL Rx Only Di... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Lannett Company, Inc. |
| Oct 25, 2019 | Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Novitium Pharma LLC |
| Oct 25, 2019 | Novitium Pharma Ranitidine Capsules 150 mg 60 capsules Rx Only Manufactured b... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Novitium Pharma LLC |
| Oct 25, 2019 | Novitium Pharma Ranitidine Capsules 300 mg 30 capsules Rx Only Manufactured b... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Novitium Pharma LLC |
| Oct 25, 2019 | Novitium Pharma Ranitidine Capsules 300 mg 100 capsules Rx Only Manufactured ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Novitium Pharma LLC |
| Oct 23, 2019 | Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 80 tablets per ... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 50 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 30 tablets per ... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 95 t... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 24 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 160 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 90 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 40 t... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 200 tablets pe... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 24 t... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 65 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 65 t... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 150 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 95 tablets per... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 8 tablets. [ND... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 90 t... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 23, 2019 | Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 60 tablets per ... | CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine. | Class II | Perrigo Company PLC |
| Oct 22, 2019 | Cool Mint Tablets Maximum Strength Zantac 150 mg Sanofi Distributed by: Chatt... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219,... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Maximum Strength Zantac 150 mg Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Compa... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Cool Mint Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sa... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Compa... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 22, 2019 | Regular Strength Zantac 150 mg Distributed by: Chattem, Inc., a Sanofi Compan... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Sanofi-Aventis U.S. LLC |
| Oct 17, 2019 | AVKARE Ranitidine Hydrochloride Capsules 150 mg 500 Capsules Rx Only NDC 4229... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Oct 17, 2019 | AVKARE Ranitidine Hydrochloride Capsules 300 mg 500 Capsules Rx Only NDC 4229... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 150 mg, a.) 65 count bottles (NDC 49035-404-61) b.) 1... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets 75 mg, a.) 30 count bottles (NDC 63868-482-30), 60 count b... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 150 mg, 40 count bottles, NDC 11673-849-40 (Target) OTC. | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger) | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC. | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 63868-480-24), b.) ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 75 mg, a.) 30- count bottles (NDC 0363-0131-30), b.) ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 1, 2019 | Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 30142-505-34), b.) ... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Dr. Reddy's Laboratories, Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.